Le Lézard
Classified in: Health
Subject: ATY

ENDOLOGIX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Endologix, Inc. - ELGX


NEW ORLEANS, Dec. 15, 2017 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Endologix, Inc. (NasdaqGS: ELGX).  

Kahn Swick & Foti, LLC ("KSF") - - not all law firms are created equal.  Visit www.ksfcounsel.com to learn more about KSF. (PRNewsfoto/Kahn Swick & Foti, LLC)

On August 2, 2016, the Company issued a press release in which CEO John McDermott touted the performance of one of its devices, the Nellix EndoVascular Aneurysm Sealing System ("Nellix EVAS System"), based on results from the investigational device exemption (IDE) clinical trial, the EVAS FORWARD-IDE Study, and the Company's "confidence in its long-term potential to be a market leading device" with potential FDA approval "in the first quarter of 2017" or possibly later "into the third quarter of 2017."  Then, on November 16, 2016, the Company revealed that the FDA had requested additional data for a two year period for patients registered in the IDE study.  Finally, on May 17, 2017, the Company disclosed that it had abandoned FDA approval of the first generation Nellix device, but would seek approval of a second generation Nellix device, requiring a separate clinical trial and pushing the timeline for approval of Nellix to 2020.

KSF's investigation is focusing on whether Endologix's officers and/or directors breached their fiduciary duties to Endologix shareholders or otherwise violated state or federal laws. 

If you have information that would assist KSF in its investigation, or have been a long-term holder of Endologix shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]).

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
206 Covington St.
Madisonville, LA 70447

 

SOURCE Kahn Swick & Foti, LLC


These press releases may also interest you

at 18:23
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...

at 17:55
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...

at 17:20
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...



News published on and distributed by: